Inspire Investing LLC Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Inspire Investing LLC cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 64.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,813 shares of the specialty pharmaceutical company's stock after selling 15,985 shares during the quarter. Inspire Investing LLC's holdings in Collegium Pharmaceutical were worth $341,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Caxton Associates LP bought a new position in shares of Collegium Pharmaceutical in the first quarter valued at about $1,730,000. Foundry Partners LLC acquired a new stake in Collegium Pharmaceutical during the second quarter worth approximately $492,000. LSV Asset Management boosted its holdings in shares of Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company's stock worth $14,773,000 after acquiring an additional 248,751 shares during the period. O Shaughnessy Asset Management LLC grew its position in shares of Collegium Pharmaceutical by 159.3% in the first quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company's stock valued at $1,775,000 after purchasing an additional 28,100 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company's stock valued at $90,479,000 after purchasing an additional 17,942 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on COLL. HC Wainwright boosted their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, September 5th. Needham & Company LLC restated a "hold" rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Truist Financial boosted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a report on Friday, August 9th. Finally, StockNews.com raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $42.60.

Collegium Pharmaceutical Price Performance

Shares of COLL traded down $0.49 during midday trading on Friday, hitting $38.44. The company's stock had a trading volume of 166,913 shares, compared to its average volume of 445,663. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 16.02 and a beta of 0.94. Collegium Pharmaceutical, Inc. has a one year low of $20.95 and a one year high of $42.29. The company's fifty day simple moving average is $37.65 and its two-hundred day simple moving average is $35.46.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. During the same quarter last year, the firm earned $1.13 earnings per share. The company's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.79 earnings per share for the current fiscal year.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm's stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares of the company's stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the business's stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares of the company's stock, valued at $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.